Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNMV0D)

Drug Name

JAB-3312 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein-tyrosine phosphatase SHP-2 (PTPN11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TNO155	DMZ60X4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
JAB-3068	DMSGEU6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
BBP-398	DM572ZL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
SAR442720	DMTAOPC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
RLY-1971	DMUT4YZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
PF-07284892	DMQ6F8X	Aggressive cancer	2A00-2F9Z	Phase 1	[7]
A380	DMXOZDP	Aggressive cancer	2A00-2F9Z	Phase 1	[8]
RG6433	DMZM06U	Aggressive cancer	2A00-2F9Z	Phase 1	[9]
NSC-87877	DMEYKXL	Discovery agent	N.A.	Patented	[10]
Dodecane-Trimethylamine	DMUPMCZ	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein-tyrosine phosphatase SHP-2 (PTPN11)	TT7WUAV	PTN11_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04720976) JAB-3312 Activity in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of AbbVie.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of Revolution Medicines.
6	Clinical pipeline report, company report or official report of Relay Therapeutics.
7	SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023 Aug 4;13(8):1789-1801.
8	Clinical pipeline report, company report or official report of Klus Pharma
9	Clinical pipeline report, company report or official report of Roche
10	Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem. 2008 Aug 28;51(16):4948-56.
11	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.